Home Featured Page 15

Featured

Latest

Rethinking Addiction and Treatment Models: Is the Recovery Community Ready for Psychedelics?

Psychedelics Today Gifting Guide 2024

The Mystical Roots of Psychedelics: Exploring Dreams and the Liminal State

SCOOP: PSFC’s $130M Roadmap to Shape the Future of Psychedelic Philanthropy

Pα+ Psychedelic Bulletin #183:

Microdosing as a Coaching Tool: Navigating the Path to Inner Truth

Funding the Future of Psychedelic Medicine in Europe: An Interview with...

Vital 4: Informational Session and Q+A

Transforming Trauma: Community, Connection, and the Healing Power of Vulnerability

Women and Psychedelics: History’s Untold Stories

Pα+ Psychedelic Bulletin #165: A Closer Look at a Buzzy Oral...

Understanding Microdosing: Integrating Small Doses for Big Therapeutic Gains

In Brief: ICER Issues Final Evidence Report and Recommendations Re: MDMA-Assisted...

Building a Unified Psychedelic Future: Ethics, Standards, and a Path to...

What is MDMA’s FDA Approval Status? A Look Ahead

1...141516...277 Page 15 of 277

Rethinking Addiction and Treatment Models: Is the Recovery Community Ready for...

Psychedelics Today Gifting Guide 2024

The Mystical Roots of Psychedelics: Exploring Dreams and the Liminal State

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Rethinking Addiction and Treatment Models: Is the Recovery Community Ready for Psychedelics?

Psychedelics Today Gifting Guide 2024

The Mystical Roots of Psychedelics: Exploring Dreams and the Liminal State

SCOOP: PSFC’s $130M Roadmap to Shape the Future of Psychedelic Philanthropy

Pα+ Psychedelic Bulletin #183:

Microdosing as a Coaching Tool: Navigating the Path to Inner Truth

Funding the Future of Psychedelic Medicine in Europe: An Interview with...

Vital 4: Informational Session and Q+A

Transforming Trauma: Community, Connection, and the Healing Power of Vulnerability

Women and Psychedelics: History’s Untold Stories

Pα+ Psychedelic Bulletin #165: A Closer Look at a Buzzy Oral...

Understanding Microdosing: Integrating Small Doses for Big Therapeutic Gains

In Brief: ICER Issues Final Evidence Report and Recommendations Re: MDMA-Assisted...

Building a Unified Psychedelic Future: Ethics, Standards, and a Path to...

What is MDMA’s FDA Approval Status? A Look Ahead

EDITOR PICKS

Rethinking Addiction and Treatment Models: Is the Recovery Community Ready for...

Psychedelics Today Gifting Guide 2024

The Mystical Roots of Psychedelics: Exploring Dreams and the Liminal State

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY